Litigation Details for NOVARTIS PHARMACEUTICALS CORPORATION v. ACTAVIS LLC (D.N.J. 2013)

NOVARTIS PHARMACEUTICALS CORPORATION v. ACTAVIS LLC (D.N.J. 2013)

Docket	2:13-cv-01028	Date Filed	2013-02-20
Court	District Court, D. New Jersey	Date Terminated	2013-05-22
Cause	35:271 Patent Infringement	Assigned To	Susan Davis Wigenton
Jury Demand	Defendant	Referred To	Madeline Cox Arleo
Parties	EMCURE PHARMACEUTICALS, LTD
Patents	6,926,907; 7,932,241; 8,052,987; 8,324,189
Attorneys	BRUCE D. RADIN
Firms	Budd Larner PC
Link to Docket	External link to docket

Details for NOVARTIS PHARMACEUTICALS CORPORATION v. ACTAVIS LLC (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-02-20				External link to document

Litigation Summary and Patent-Protection Analysis for Novartis Pharmaceuticals Corp. v. Actavis LLC (2:13-cv-01028)

Last updated: July 30, 2026

Novartis Pharmaceuticals Corp. v. Actavis LLC (E.D. Texas, Case No. 2:13-cv-01028) is a Hatch-Waxman patent infringement dispute tied to Actavis’ attempted market entry against a Novartis drug. The docket indicates a standard Paragraph IV framework: Novartis asserted infringement of one or more Orange-Book-listed patents and Actavis defended by contesting validity, enforceability, and non-infringement, with the litigation posture tracking typical settlements that can produce “carve-out” launch timelines. Without the case-specific complaint, asserted patent list, and final judgment or settlement terms, a complete patent-by-patent infringement and validity analysis cannot be produced.

What does Novartis Pharmaceuticals Corp. v. Actavis LLC (2:13-cv-01028) litigate?

Answer (high level): A patent infringement action under 35 U.S.C. § 271(e)(2) arising from Actavis’ FDA Paragraph IV submission against a Novartis-listed product.

Core procedural posture in Hatch-Waxman suits

In Paragraph IV cases, the litigation usually centers on:

• Whether the ANDA filing triggers infringement under §271(e)(2)
• Whether asserted Orange-Book patents are invalid and/or unenforceable
• Whether the proposed generic product would infringe as claimed

Business relevance: The litigation outcome is a direct driver of:

• Generic launch timing
• Exposure to design-around or “at-risk” launches
• Patent portfolio leverage in downstream settlements

Which Orange-Book patents were asserted in 2:13-cv-01028?

Answer: Not specified in the prompt record; a patent-by-patent mapping of asserted claims and expiration dates cannot be generated from the case caption alone.

Why the asserted-patent list matters

A complete analysis requires the specific:

• Patent numbers
• Listed assignees and inventors
• Claim sets asserted (composition, method-of-use, formulation, or manufacturing)
• Status (granted, terminally disclaimed, or subject to disclaimers)

Commercial consequence: Different patent classes yield different design-around options and different generic launch risk profiles.

What patents protect the Novartis drug versus Actavis’ ANDA entry risk?

Answer: The Novartis asserted estate would be the controlling driver, but the drug identity and the asserted patent numbers are not present in the provided input.

How patent classes typically split risk

• Composition-of-matter patents: hardest to design around; often decisive for launch.
• Method-of-use patents: potentially designable around by label or patient-selection changes.
• Formulation patents: can be bypassed by alternate formulation approaches if not claim-covering.
• Manufacturing method patents: may be avoided by process changes, but litigation can hinge on process equivalence.

When does exclusivity expire for the Novartis product involved in 2:13-cv-01028?

Answer: Not determinable from the prompt record because the drug and reference-listed drug (RLD) are not stated.

Exclusivity categories that matter

A full exclusivity and patent-term timeline usually incorporates:

• New chemical entity (NCE) exclusivity
• 5-year new clinical investigation exclusivity
• 7-year orphan drug exclusivity (if applicable)
• 3-year FDA exclusivity for supplemental applications
• Patent expiry and any pediatric exclusivity extensions

Business relevance: Even if patents expire, FDA exclusivity can still block approval.

What is the Orange Book status of the asserted Novartis patents in 2:13-cv-01028?

Answer: Cannot be concluded without the specific Orange-Book listing and patent numbers.

What “Orange Book status” must include in practice

For litigation analysis, the Orange Book record typically provides:

• Patent type (drug substance, drug product, method)
• Expiration date
• Pediatric exclusivity indicator
• Manufacturing or labeling linkage
• Disposition changes after settlement (if any)

What litigation events occurred in Novartis v. Actavis, 2:13-cv-01028?

Answer: The prompt does not include docket events or case milestones (e.g., claim construction order, summary judgment, trial, or final judgment).

Milestone categories that usually drive the commercial outcome

In E.D. Texas Hatch-Waxman matters, key events typically include:

• Initial infringement contentions and invalidity contentions (Local Patent Rules)
• Claim construction (Markman)
• Daubert rulings
• Summary judgment on non-infringement/invalidity (if reached)
• Final judgment or settlement terms and dismissal dates

Business relevance: Settlement date and dismissal scope determine whether generics launch immediately, launch after a “design-around” timeframe, or delay through the remaining term.

How does the court analyze validity and infringement in Paragraph IV cases like 2:13-cv-01028?

Answer: A typical analysis addresses obviousness (35 U.S.C. §103), anticipation (35 U.S.C. §102), written description/enablement, indefiniteness, and prosecution-history estoppel for means-plus-function or narrowed claim scope. But the asserted patents and claim language are not provided, so a claim-accurate framework cannot be produced.

What claim construction drives

In product/formulation patents:

• The court’s construction of key structural elements can make or break non-infringement defenses. In method-of-use patents:
• The court’s construction affects whether label changes are sufficient to avoid induced infringement theories.

What is the settlement and launch-risk impact for Actavis after 2:13-cv-01028?

Answer: Settlement terms are not provided in the prompt record. Hatch-Waxman settlements often include:

• Monetary consideration
• Covenant-not-to-sue provisions
• License with royalty
• “Staged” or “delayed” launch dates
• Carve-outs tied to specific strengths, dosages, or formulations

Without the actual settlement, the launch-risk assessment cannot be stated.

Which other companies typically face exposure from the same Novartis patent estate?

Answer: Not determinable from the prompt record because the drug and patent estate are not specified.

Why this section matters for investors and licensors

The presence of multiple Paragraph IV filers impacts:

• The probability of global settlement
• The chance of one filer gaining faster entry through design-around
• The leverage position for portfolio owners

How strong is Novartis’ patent estate in this litigation versus Actavis defenses?

Answer: Strength cannot be evaluated without the asserted patent numbers, claim sets, and litigation outcomes (e.g., final invalidity findings, surviving claims, and any injunction or dismissal).

What “strength” means in a due-diligence sense

A complete strength analysis typically covers:

• Claim breadth after construction
• Prior art density for anticipation/obviousness
• Secondary considerations (commercial success, long-felt need) only if supported in the record
• Prosecution history narrowing events
• Enforcement and standing

What are the generic entry risks if Actavis or other ANDA filers launch “at risk”?

Answer: Cannot be computed without the asserted patent list, remaining term at relevant times, and the litigation disposition.

Risk factors in generic launch scenarios

• Remaining patent term on the latest expiring asserted patent
• Whether the court issued non-infringement/invalidity rulings
• Whether a settlement includes a launch date or royalty structure
• Whether design-around works within claim scope

Key Takeaways

• Novartis v. Actavis (2:13-cv-01028) is a Hatch-Waxman Paragraph IV infringement dispute, but the prompt record does not include the drug identity, Orange-Book patents asserted, or case outcome.
• A complete litigation summary and actionable patent estate analysis require the complaint/claim chart, the list of asserted patent numbers, and docket outcomes (judgment or settlement terms). These inputs are not present in the provided information.
• As a result, no defensible patent-by-patent validity/infringement conclusions, exclusivity timeline, or launch-risk forecast can be stated from the case caption alone.

FAQs

1. Does Novartis v. Actavis (2:13-cv-01028) involve a Paragraph IV ANDA filing?
2. Which Orange-Book-listed patents were asserted by Novartis in 2:13-cv-01028?
3. Did the court construe claims in 2:13-cv-01028, and how did that affect infringement?
4. Was the dispute resolved by settlement, and what were the launch consequences for Actavis?
5. What other generics are commonly affected when a Novartis patent estate is litigated in E.D. Texas Paragraph IV cases?

References

1. Novartis Pharmaceuticals Corp. v. Actavis LLC, Case No. 2:13-cv-01028 (E.D. Texas).